Overall rank by patents
#33,793
of 49,997 tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Venenum Biodesign, LLC
USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Venenum ranks #33,793 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.
- #33,793
- of 49,997 US assignees by volume
- 46th percentile
- by Innovation Score (33.9/100)
- 18.4
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R33793 · US Corporation #33,793 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 8 grants
- MID-PACK #33,793/49,997
- PHOTO-FINISH Vantage Robotics
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 33.9/100
- CLAIMS-RICH 18.4 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2020–2024 · 5y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Vantage Robotics, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Innovation-score neighbourhood around Venenum
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Venenum Biodesign · this assignee 34
Venenum Biodesign · this assignee
34 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Venenum's Innovation Score is 33.9/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Where Venenum's grants concentrate
Venenum Biodesign, LLC is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2023. By volume, Venenum sits between Vantage Robotics, LLC and VF Corporation.
Venenum's three-year grant acceleration
Venenum Biodesign, LLC shows 4 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Venenum's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Vantage Robotics
Vantage Robotics, LLC
8 patents
- Vaxine PTY
Vaxine PTY Ltd.
8 patents
- Veer Gear
Veer Gear LLC
8 patents
- Veir
Veir, Inc.
8 patents
- Verastem
Verastem, Inc.
8 patents
- Verve Therapeutics
Verve Therapeutics, Inc.
8 patents
- Vestre AS
Vestre AS
8 patents
- VF
VF Corporation
8 patents
- Venenum Biodesign ◀
Venenum Biodesign, LLC
8 patents
What this shows Venenum holds 8 patents at rank #33,765, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Venenum
By rank, the assignees closest to #33,765 in granted patent volume.
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Venenum's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Venenum's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 46th percentile higher than 46% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 25.0% |
| 2021 | 2 | 25.0% |
| 2022 | 2 | 25.0% |
| 2023 | 1 | 12.5% |
| 2024 | 1 | 12.5% |
Which technologies does Venenum Biodesign, LLC patent most?
Top 6 of 6 technology areas
What to do with this data
Venenum Biodesign, LLC's patent record in context - here's where to go next.
- Venenum Biodesign, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #33,793 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Venenum Biodesign, LLC against Vantage Robotics, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 33.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.